Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus versus mycophenolate mofetil for autoimmune hepatitis with incomplete response to first-line therapy
NL-OMON49891Phase 3Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Jan 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tacrolimus, mycophenolate mofetil and prednisolone in autoimmune hepatitis (AIH) (2 arms), sponsored by Leiden University Medical Center. Started Jan 2022; status: recruiting.
02
Drugs
tacrolimusmycophenolate mofetilprednisolone
03
Conditions
autoimmune hepatitis (AIH)
Beyond the preview
Go deeper on NL-OMON49891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49891.